News & Events


Our latest Press Releases

Tubulis partners TUB-010, its CD30-targeting IND-ready ADC, with Oncoteq

Tubulis publishes article in Molecular Cancer Therapeutics on advantages of its proprietary P5/Tubutecan platform

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients


Meet Tubulis live